InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.420
-0.040 (-1.63%)
At close: Aug 26, 2026, 4:00 PM EDT
2.423
+0.003 (0.13%)
After-hours: Aug 26, 2026, 7:30 PM EDT
InflaRx Revenue
InflaRx had revenue of -10.10K EUR in the twelve months ending June 30, 2026. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%.
Revenue (ttm)
-10.10K EUR
Revenue Growth
-82.31%
P/S Ratio
-30,903.91
Revenue / Employee
-155 EUR
Employees
65
Market Cap
356.63M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Clinuvel Pharmaceuticals | 64.24M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| ProQR Therapeutics | 21.05M |
| Palisade Bio | 500.00K |
| SAB Biotherapeutics | 114.70K |
IFRX News
- 6 days ago - InflaRx Announces Participation in September Investor Conferences - GlobeNewsWire
- 20 days ago - InflaRx Earnings release: Q2 2026 - Filings
- 20 days ago - InflaRx files $250M mixed securities shelf - TheFly
- 20 days ago - InflaRx Registration statement: Registration filing - Filings
- 20 days ago - InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 27 days ago - InflaRx to Report Second Quarter 2026 Results on August 6, 2026 - GlobeNewsWire
- 2 months ago - InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - GlobeNewsWire
- 3 months ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly